Tag: drug
Pfizer says on lookout for mid-size drug deals
by on May.02, 2012, under Health and Fitness
(Reuters) – Pfizer Inc, which last week agreed to sell its baby formula business for almost $12 billion, is on the hunt for companies with promising new treatments for diabetes, cancer and neurological conditions, and willing to spend $4 billion o…
View full post on Yahoo! Health News
Actelion breathes easy on "best case" new drug data
by on Apr.30, 2012, under Health and Fitness
ZURICH/LONDON (Reuters) – A new lung and heart drug from Actelion beat expectations in a key clinical trial, giving a much-needed boost to its pipeline and providing Europe's leading biotech company with a viable successor to its current top s…
View full post on Yahoo! Health News
Australia’s Biota to take over drug maker Nabi
by on Apr.23, 2012, under Health and Fitness
MELBOURNE (Reuters) – Australian flu drug maker Biota Holdings has agreed to take over U.S. firm Nabi Biopharmaceuticals to create a $258 million group and move to the United States, where investors value biotech research more highly than in Austr…
View full post on Yahoo! Health News
Novo Nordisk rejects diabetes drug Victoza complaint
by on Apr.20, 2012, under Health and Fitness
COPENHAGEN (Reuters) – Danish drugmaker Novo Nordisk rejected a consumer advocacy group's complaint about its big-selling diabetes drug Victoza as groundless and said it did not expect U.S. regulators to take any action. Its shares initially d…
View full post on Yahoo! Health News
Actelion sees data on big drug hope in coming weeks
by on Apr.19, 2012, under Health and Fitness
ZURICH (Reuters) – Europe's largest biotech company Actelion said it expects results of a key late-stage trial on heart and lung disease drug macitentan in the next few weeks after a strong Swiss franc and competition hit first-quarter profit….
View full post on Yahoo! Health News
Gilead hepatitis C drug proves itself in study
by on Apr.19, 2012, under Health and Fitness
(Reuters) – An experimental hepatitis C drug acquired by Gilead Sciences Inc when it paid nearly $11 billion to buy Pharmasset has produced encouraging results in a closely watched clinical trial, results of which were released in Barcelona. The U…
View full post on Yahoo! Health News
Newron agrees Parkinson’s drug deal with Zambon
by on Apr.05, 2012, under Health and Fitness
ZURICH (Reuters) – Italian drug maker Newron has signed a strategic collaboration and licensing deal for its Parkinson's disease drug safinamide with Italian drugs and chemicals maker Zambon which involves Zambon taking a 9.1 percent stake in …
View full post on Yahoo! Health News
GSK says new data support filing of diabetes drug
by on Apr.03, 2012, under Health and Fitness
LONDON (Reuters) – GlaxoSmithKline will push ahead with plans to file its experimental once-weekly diabetes drug albiglutide for regulatory approval, following the read-out from a series of clinical trials. Albiglutide belongs to the same class of…
View full post on Yahoo! Health News
Novartis lung drug meets goals in late-stage trials
by on Apr.02, 2012, under Health and Fitness
ZURICH (Reuters) – A Novartis lung drug met its main goals in three late-stage studies in patients with chronic obstructive pulmonary disease (COPD), often known as smokers' cough, the Swiss drugmaker said on Monday, giving its respiratory pip…
View full post on Yahoo! Health News
GSK’s new once-daily HIV drug matches Merck rival
by on Apr.02, 2012, under Health and Fitness
LONDON (Reuters) – A new once-daily AIDS drug from GlaxoSmithKline and its partner Shionogi proved just as good as Merck & Co's twice-daily rival Isentress in a late-stage clinical trial, boosting hopes for the product. Both GSK's new drug…
View full post on Yahoo! Health News
